Bai Cheng Pharmaceutical: Sitagliptin Metformin Controlled-Release Tablets 50mg are selected in the twelfth batch of centralized procurement.

Baicheng Pharmaceutical announced that its wholly-owned subsidiary, Zhejiang Saimei Pharmaceutical Co., Ltd., participated in the twelfth national centralized procurement organized by the National Medical Products Administration. The sitagliptin and metformin sustained-release tablets were selected in this procurement. This medication is suitable for adult patients with type 2 diabetes who are undergoing combination therapy with sitagliptin and metformin sustained-release tablets. The selected specifications include sitagliptin phosphate 50mg and metformin hydrochloride 500mg, as well as sitagliptin phosphate 100mg and metformin hydrochloride 1000mg. For the year 2025, Saimei Pharmaceutical has not yet realized sales revenue from the above-mentioned selected products.